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Tajuk: Nilai Prognostik Subjenis Molekul dan Faktor-faktor Lain Terhadap Kemandarian 
Tanpa Penyakit dalam Kalangan Wanita dengan Penyakit Kanser Payudara di Hospital USM. 
Pengenalan: Dengan kejadian baru sebanyak 18,206 pesakit pada tahun 2007-2011, kanser 
payudara adalah kanser yang paling kerap di Malaysia. Kira-kira 2,572 pesakit mati akibat 
kanser payudara pada tahun 2012. 
Objektif: Kajian ini mengakses kemandarian bebas penyakit 5 tahun, subjenis molekul dan 
faktor-faktor prognostik lain untuk kanser payudara. 
Kaedah: Kajian secara retrospektif satu pusat dalam kalangan 208 pesakit dengan peyakit 
kanser payudara tanpa metastasis yang telah menerima pembedahan antara tahun 2007 dan 
2015. Data yang dikumpul termasuk demografi pesakit, ciri-ciri tumor, profil histopatologi 
dan rawatan. Pesakit dibahagikan kepada empat kumpulan: Luminal A: ER + dan / atau PR + 
dan HER2- Luminal B: ER + dan / atau PR + dan HER2 +; HER-2 diperkaya: ER-, PR- dan 
HER2 +; Triple negatif: ER-, PR- dan HER2-. Nilai nisbah bilangan nodus positif dan nodus 
diperiksa dikelaskan kepada 0, ≤0.250,> 0.20 dan ≤ 0.65 serta > 0.65. Analisis Kaplan Meier 
dijalankan. Regresi cox proportional hazard digunakan untuk mengenalpasti faktor prognostic. 
Keputusan: Kadar kemandirian tanpa penyakit antara 208 pesakit adalah 55% (95% SK:.46.6-
62.7) Jenis kanser antara pesakit adalah: Luminal A (35.2%), Luminal B (29.0%), HER2-
enriched (18.1%), dan Triple negatif (17.6%). Dalam analisis ringkas, subjenis molekul tidak 
dikaitkan dengan kemandirian tanpa penyakit. Namun begitu, bilangan nodus positif (LNs) 
serta LNR adalah faktor prognostik bagi kemandirian tanpa penyakit. Dalam analisis berganda,  
LNs menjadi tidak bermakna dan LNR kekal sebagai faktor prognostic, serta menunjukkan 
risiko pesakit mengalami sebarang kejadian semula atau kematian untuk adalah lebih tinggi 
(NB 1.17; 95% CI: 1.10 – 1.26) bagi setiap peningkatan  0.1 unit dalam LNR. 
Kesimpulan: Kajian ini melaporkan jenis kanser payudara jenis Luminal adalah subjenis 
kanser payudara yang paling biasa di kalangan pesakit wanita. Kajian ini juga menunjukkan 
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bahawa LNR adalah faktor prognostik yang lebih baik dalam meramalkan kemandirian tanpa 




Title: Prognostic Value of Molecular Subtypes and Other Factors on  Disease-Free Survival 
in Women with Breast Cancer at Universiti Sains Malaysia Hospital. 
Introduction: Breast cancer is the most common cancer in Malaysia with a 5-year incidence 
of 18,206 patients during 2007-2011. Approximately 2,572 patients died of breast cancer in 
2012 in Malaysia.  
Objective: The study assessed the five-year disease-free survival (5-y DFS), distribution of 
molecular subtypes and other prognostic factors of breast cancer.  
Methods: A single-center retrospective review was conducted on 208 patients with non-
metastatic, operable breast cancer treated with mastectomy or breast-conserving surgery 
between 2007 and 2015. Data collected included patients’ demographics, tumour’s 
characteristics, histopathological profiles, receptor status and treatment modalities. Molecular 
subtypes of breast cancer were subdivided into four groups: Luminal A: ER+ and/or PR+ and 
HER2- Luminal B: ER+ and/or PR+ and HER2+; HER-2 enriched: ER-, PR- and HER2+; 
Triple negative: ER-, PR- and HER2-. Ratio of positive lymph nodes (LNs) and dissected LNs 
was classified as 0, ≤0.20, >0.20 and ≤ 0.65 and > 0.65. Kaplan-Meier survival analysis was 
performed. Cox proportional hazards regression was used to determine prognosis factor.  
Result: The distribution of molecular subtypes among 208 patients was: Luminal A (35.2%), 
Luminal B (29.0%), HER2-enriched (18.1%), and Triple-negative (17.6%). In univariable 
analysis, the molecular subtype was not associated with DFS. However, both absolute number 
of positive lymph nodes and the LNR were significant prognostic factors of DFS. In 
multivariable analysis, the positive LNs lost significance and the LNR remained as a 
prognostic factor of DFS, patients had increased risk (aHR: 1.17; 95% CI: 1.10 - 1.26)   to 
experience any recurrence or death for every increasing of 0.1 unit in LNR when radiotherapy 
was adjusted for. 
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Conclusion: The present study reported the Luminal type breast cancer was the most common 
subtype of breast cancer among female patients. The study also demonstrates that LNR is a 
better prognostic factor in predicting DFS than the absolute number of positive LNs.       
Molecular subtype is not a significant prognostic factor.
1 
 
CHAPTER 1 - INTRODUCTION 
1.1 Global Epidemiology of Breast Cancer 
Breast cancer is the second most common cancer in the world and the most frequent cancer 
among women by far, with an estimated of 1.67 million new cases diagnosed in 2012 (25% of 
all cancers and 12 % of new cancer) (Ferlay et al., 2015). In term of mortality, the breast cancer 
caused around 522,000 deaths in 2012 and ranked as the fifth cause of death from cancer 
overall. In less developed countries, the breast cancer is the most frequent cause of cancer-
related death in women population (324,000 deaths, 14.3%). It is the second cause of cancer-
related death after lung cancer in developed countries (15.4%) and most common cause of 
cancer death in developing nation (14.3%) (Ferlay et al., 2015). 
 
In USA, the American Cancer Society estimates more than 250,000 women were diagnosed 
with invasive breast cancer in 2017. However, the death rate from breast cancer had decreased 
by 1.9% per year among female patients in the nation (Ryerson et al., 2016).  
 
In Asia-Pacific region, 404,000 cases of female breast cancer were diagnosed during 2012, 
corresponding to a rate of 30 per 100,000. In Asia, the incidence of breast cancer was lower 
compared to Northern America and Europe (Ferlay et al., 2015). Consistent with the 
worldwide figure, breast cancer was the most common cancer among women in the Asia-
Pacific region, accounting for 18% of all type of cancer. In term of mortality, 116,000 females 
were estimated to have died from breast cancer in 2012, representing 22% of total death in 
global (Youlden et al., 2014). 
 
A research noted the incidence rates of breast cancer were relatively high in Southeastern Asia 
(Philippines, Singapore and Thailand) when compared to other region in Asia such as China, 




1.2 Epidemiology of Breast Cancer in Malaysia 
Breast cancer was the most common cancers, leading to death among women in Malaysia. A 
total of 18,206 cases of breast cancer were diagnosed during 2007-2011, accounting for 17.7% 
of all cancer incidence (Azizah et al. 2016).  The GLOBALCAN 2012 study estimated the 
age-standardised mortality rate is 18.9 per 100000 population (Ferlay et al. 2015). 
Approximately 2,572 patients died of breast cancer in 2012. Larger increment in breast cancer 
mortality was observed in Malaysia as compared to other regions in Asia such as Hong Kong 
and Singapore (Youlden et al., 2014).  
 
Among races in Malaysia, the overall cumulative risk of having breast cancer was 3.4 across 
the population and was highest among Chinese (4.5%) and lowest among Malays (2.9%).  The 
incidence rate increase since the second decade of life and the peak incidence occurred in the 
5th decade of life. The proportion of breast cancer detected at stage I, II, III and IV were 20%, 
20%, 23% and 37%, respectively (Azizah et al., 2016). 
 
1.3 Justification of The Study 
Estrogen receptor, progesterone receptor and HER2 receptor are important in the management 
of breast cancer as it will further classify breast cancer into four distinct molecular subtypes, 
i.e., Luminal A, Luminal B, HER2 overexpressing and Triple-negative breast cancer, along 
with different prognostic implications (Carey et al., 2006). In Malaysia, studies on the topic 
regarding the prognostic value of breast cancer molecular subtype or hormonal receptor / 
HER2 receptor status are very few. To the best of current knowledge, only one study had been 
conducted in Sarawak determined the prevalence and distribution pattern of each molecular 
subtype in Malaysia (Devi et al., 2012), and none has been published with regards to the 
prognostic value of distinct subtype in the Malaysian population.  
 
Yip et al. reviewed 421 breast cancer research in Malaysia from 1996 to 2014 and suggested 
future research on the reason why the Malay ethnicity had a poorer survival may be warranted 
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by studying pharmacogenomics in connection with chemotherapy as a possible factor (Yip et 
al., 2014). Another author recommended the prognostic value of various biomarkers, e.g., 
HER-2, in local populations (Ong andYip, 2003) to be studied in future research. Even though 
a similar study by Leow et al. (2007) had been conducted to determining prognostic factor for 
overall survival of breast cancer, the study did not include HER-2 receptor status and the 
information on ER and PR receptor status were limited, hence the distribution of molecular 
subtype was not reported. In addition to that, there is limited published study to review the 
locoregional recurrence of breast cancer in Malaysia.  
 
This study was conducted in Kelantan, a state located in northern region of Peninsular 
Malaysia. This research aimed to examine the distribution pattern of molecular subtype among 
patients, and the prognostics value of molecular subtypes and/or ER/PR/HER2 receptors in 
women with breast cancer with a recent population data (2007-2015). DFS was used to provide 
some information on the locoregional recurrence for Malaysian female diagnosed with breast 
cancer.  
 
Along with molecular subtype as the primary interest, this study also aimed to investigate the 
other potential patient-related, clinical and pathological related and treatment-related factor 
toward breast cancer DFS.  With the above interest in mind, this single centre study was 
expected to eventually provide additional value to improve the breast cancer management in 
patients living in Kelantan, and reasonably to be extrapolated to whole Malaysian breast cancer 
population.  
 
1.4 Research Questions 
• What were the overall locoregional recurrence and five-year disease-free survival (5-y 
DFS) for women diagnosed with non-metastatic, operable breast cancer treated with 
mastectomy or breast-conserving surgery at USM hospital? 
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• What was the distribution of molecular subtype among women diagnosed with non-
metastatic, operable breast cancer treated with mastectomy or breast-conserving surgery 
at USM hospital? 
• Was the molecular subtype the prognostic factor of the DFS for women diagnosed with 
non-metastatic, operable breast cancer treated with mastectomy or breast-conserving 
surgery at USM hospital? 
• What were the other factors associated with DFS for women diagnosed with non-
metastatic, operable breast cancer treated with mastectomy or breast-conserving surgery 
at USM hospital? 
 
1.5 General Objectives 
• To study the overall locoregional recurrence, 5-y DFS and prognostic factor among 
women diagnosed with non-metastatic, operable breast cancer treated with mastectomy or 
breast-conserving surgery at USM hospital 
 
1.6 Specific Objectives 
• To determine the overall locoregional recurrence and 5-y DFS among women diagnosed 
with non-metastatic, operable breast cancer treated with mastectomy or breast-conserving 
surgery at USM hospital 
• To determine the distribution of molecular subtype survival among women diagnosed with 
non-metastatic, operable breast cancer treated with mastectomy or breast-conserving 
surgery at USM hospital 
• To determine the association of molecular subtype, patient-related, clinical and 
pathological related and therapy-related factor toward 5-y DFS among women diagnosed 
with non-metastatic, operable breast cancer treated with mastectomy or breast-conserving 
surgery at USM hospital 
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1.7 Research Hypothesis 
• The molecular subtype was associated with 5-y DFS among women diagnosed with non-
metastatic, operable breast cancer treated with mastectomy or breast-conserving surgery 
at USM hospital. 
 
• The patient-related factors, clinical and pathological-related factors, therapy-related 
factors were associated with 5-y DFS among women diagnosed with non-metastatic, 





CHAPTER 2 - LITERATURE REVIEW 
2.1 Literature Search Strategies 
Literature search strategy includes using the phrase, using Boolean operator and keywords as 
well as searching by author and citation. Search engines were used to obtain the relevant 
articles on this topic. Searching databases housing relevant journals, for example, Science 
Direct, Scopus, Pubmed, Google Scholar, EBSCOhost, Springerlink, Web of Science was 
given preference over single-journal search engine except for journals, for example Online 
Access Catalogue (OPAC Krisalis) of Perpustakaan Hamdan Tahir, USM. 
Keywords: 
“breast cancer” or “breast carcinoma” or “breast tumor” AND  
“Disease-free survival” or “DFS” AND  
“molecular subtype” or “Luminal A” or “Luminal B” or “HER2 overexpress” or “Triple 
negative” or “basal-like” AND/OR 
“Hormonal receptor” or “estrogen receptor” or “ER” or “progesterone receptor” or “PR” 
AND/OR 
“HER2 receptor” or “neu” or “erbB-2” or “HER2/neu” AND 
“prognostic factor”, “associated factor”, “predictive factor” AND 











PubMed Scopus Web of 
Science 
Using Phrase 
    
breast cancer disease-free survival 2,140,000 1443 1760 1794 
breast cancer disease-free survival 
molecular subtype 
110,000 32 52 85 
breast cancer disease-free survival 
molecular subtype Malaysia 
2500 0 0 0 
Using Boolean Operators and keywords 
“Disease-free survival” AND “breast 
cancer” AND “prognostic factor”    
4230 211 182 86 
“Disease-free survival” AND “breast 
cancer” AND “molecular subtype”  
3220 32 34 38 
Citation Search Using author’s name or title of the article  
 
2.2 Survival Probability and DFS of Breast Cancer 
A review of US National Cancer Institute’s SEER database (1975-2013) revealed that the five-
year relative survival for localized, regionalized and distant breast cancer is 98.6%, 84.3% and 
24.1%, respectively (Howlader et al., 2016). The most recent data indicated that the survival 
rates for female patients with advanced breast cancer (Stage III and IV) are lower than those 
for women with earlier stage cancer. The five-year survival rate for stage III breast cancer is 
approximately 72%, while metastatic (stage IV) breast cancer possess a much lower five-year 
relative survival rate at about 22% (American Cancer Society, 2017).  
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Similarly, the data from UK (2002-2006) revealed that the five-year relative survival for stage 
I, II and III are 99%, 88% and 55% respectively. However, the five-year survival rate 
dramatically dropped to 15% for stage IV breast cancer  (Cancer Research UK, 2017). About 
one-third of patients with early-stage breast cancer will subsequently progress to metastatic 
disease (O’Shaughnessy, 2005). 
 
A population-based study based on data from 13,060 patient who were admitted to the hospital 
in Malaysia during 2000 – 2005 reported that the overall five-year survival (OS) rate was 49% 
with median survival time of 68.1 months (Abdullah et al., 2013). Other researchers in 
Malaysia reported a range from 43.5% – 69% of OS and a similar decreasing trend of OS 
across the stage I to stage IV breast cancer patient (Ibrahim et al., 2012; Nur Aishah et al., 
2008; Saxena et al., 2012). The previous study in Kelantan revealed that the breast cancer 
patient suffered a poorer prognosis compared to another region in Malaysia, in particular, the 
OS was 25.84% (Leow et al., 2007). Table 2.2 summarized studies from local society that 
showed a relatively poorer overall survival compared to developed nations. 
 
 Table 2-2: The five-year overall survival based on whole study population and staging of 
cancer at presentation during diagnosis of disease. 
Author Institution n % (95% CI) 
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81.7 72.4 39.9 12.8 
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Author Institution n % (95% CI) 

















































10,230 49.4 NA NA NA NA 
NA: Not applicable 
The development of a variety of new treatment agent and the multiplication lines of treatment 
in breast cancer have significantly reduced mortality in certain contexts. This therapeutics 
advancement has resulted in the need for new surrogate endpoints to be used in breast cancer 
research. Therefore, DFS may be obtained in shorter time frame compared to overall survival 
(OS) and had been used as surrogate endpoints in non-metastatic breast cancer settings. The 
adoption of a surrogate endpoint such as disease-free survival has been strongly influenced by 
the need to reduce the subject’s sample size and the cost of research especially in the 
randomized controlled trial (Gourgou-Bourgade et al., 2015). 
 
The researcher reported women diagnosed with breast cancer had a 5-y DFS range from 68.5% 
- 88.5%. The DFS vary across studies based on the disease presentation, patients 
characteristics and treatment received by patients (Kim et al., 2005; Diniz et al., 2016; Wen et 
al., 2016). Locoregional recurrence (LRR) after surgery especially mastectomy without distant 
metastases was common in breast cancer management, although the proportion of patient 
suffered from LRR notably varies among published studies as a result of differences in disease 
characteristics, surgical and adjuvant treatments (Clemons et al., 2001)  A local study indicated 
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the overall LRR in breast cancer patient are 16.4% after a median follow-up period of 67 
months. Table 2.3 summarizes studies from global that showed overall survival and DFS of 
breast cancer patients. 
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Mastectomy 
























NA 5-y: 72% NA 
























































Mastectomy NA NA Overall: 
16.4% 
NA: Not applicable 
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2.3 Classification of Molecular Subtype of Breast Cancer and Its Prognostic Value 
Biologic molecular and genetic knowledge has provided a new understanding of breast cancer 
that categorized into different subtype that possessed different clinical characteristic, treatment 
response and disease outcome (Prat and Perou, 2011). Although the modern microarray gene 
profiling is the best way to categorise the breast cancer subtype, the high cost and practicability 
limited the use in clinical setting hence it warranted a classification by routinely obtained 
surrogate marker (Parker et al., 2009).  
 
Many investigators had developed an alternative method by using immunochemical tests for 
estrogen receptor (ER), progesterone receptor (PR) and HER2 receptor as surrogate 
approaches for molecular subtypes of breast cancer (Goldhirsch et al., 2011). In particular, 
five intrinsic breast cancer subtypes surrogated by immunohistochemical (IHC) analysis that 
recommended by the St. Gallen International Breast Cancer Conference (2011) are: luminal A 
[ER+ and/or PR+, Ki67 low and HER2−], luminal B [ER+ and/or PR+, Ki67 high and HER2−], 
luminal HER2+ [ER+ and/or PR+, any Ki67 and HER2+], HER2 [ER−, PR−, and HER2+], 
and triple negative (TN) [ER−, PR−, and HER2−](Goldhirsch et al., 2011). However, the 
classification remained controversial. Some investigators considered any HER2+ tumor that 
is ER+ and/or PR+ to be luminal B (Carey et al., 2006; Tamimi et al., 2008). On the other 
hand,  some researcher suggested to use another biomarker Ki67 to define Luminal B into 2 
types further, one is Luminal B(HER2− ) with a high proliferation index Ki67, and the other 
one is Luminal B (HER2+) (Goldhirsch et al., 2011; Zafrani et al., 1994). However, some 
researchers against Ki67 usage and had suggested replacing with tumor grade to helping define 
the luminal B phenotypes (Brouckaert et al., 2013). To date, the debate on the cutoff point of 
Ki 67 remained. Some researchers had suggested a lower value of the Ki67 index to be used 
for better differentiation between ‘Luminal A’ and ‘Luminal B (HER2 negative)’(Bustreo et 
al., 2016). In contrast, some study reported low reproducibility of Ki67 result among the 
laboratory (Varga et al., 2012; Polley et al., 2013). The recent Saint Gallen Breast Cancer 
Conference has recommended the use of the median Ki67 value of local laboratory in 
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classifying breast cancer molecular subtype (Coates et al., 2015). In the circumstances, if Ki67 
value was unavailable, some researcher identified four categories of breast cancer: luminal A, 
luminal B, HER2 overexpressing, and basal-like or triple negative based on the status of ER, 
PR and HER2 (Perou et al., 2000; Sørlie et al., 2001). The Ki67 test was however not available 
in USM hospital. 
 
Most of the breast cancers (up to 75%) expressed either estrogen receptor or progesterone 
receptor (hormone-receptor [HR]–positive) (Setiawan et al., 2009). In general, Luminal A type 
cancers tend to be slow-growing and less aggressive compared to other subtypes. These tumors 
were associated with the better prognosis because expression of hormone receptors is a 
predictive factor of hormonal therapy’s response (Anderson et al., 2014; Blows et al., 2010). 
Most of the patients possessed Luminal A type breast cancer (44.7%) (Hennigs et al., 2016). 
 
Luminal B was similar to luminal A breast cancers in term of ER+ and/or PR+ and are further 
defined by being highly positive for Ki67 (an indicator of a large proportion of actively 
dividing cells) or HER2. About 10% of breast cancers are ER+ and/or PR+ and HER2+. 
Luminal B breast cancers tend to be higher grade and more aggressive than luminal A breast 
cancers (Parise and Caggiano, 2014). 
 
In US, about 12% of breast cancers are triple negative, so called because all three receptors 
were expressing negative status (ER-, PR-, and HER2-); however, the ethnicity is an associated 
factor in US population: Blacks are at about two times higher risk of getting triple-negative 
breast cancer than white women. Triple-negative breast cancers tend to have a poorer 
prognosis than other breast cancer types, as these subtypes are not warranted for hormonal or 




About 4% of breast cancers produce excess HER2 and do not express hormone receptors. 
These cancers tend to grow and spread more aggressively than other breast cancers. In general, 
this breast cancer subtype is associated with poorer short-term prognosis compared to ER+ 
breast cancers (Blows et al., 2010). 
 
As for Asia, a study of 346 Chinese and Japanese in New York City had a higher proportion 
of Luminal A breast cancer (66.7% and 80.0 %, respectively) when compared to Filipinos and 
Koreans. On the other hand, Filipinos had a higher proportion of HER2 positive cancers 
(45.6%) while Koreans had a higher proportion of triple-negative cancers (23.55%) (Chuang 
et al., 2012). A study reviewed 471 Japanese and noted that 65% were Luminal A, 8.7% were 
Luminal B, 12.5% were HER2 enriched, 7.9% were basal-like 5.9% were unclassified 
(Tamaki et al., 2013). Choi et al. (2007) found there was a difference in HER2 expression 
between Korean and white breast cancer patients (47.5% and 15.8%, respectively). A multi-
region gene profiling study analysed 78 samples from Chinese subjects and indicated 27% 
were Luminal A, 29% were Luminal B, 22% were HER2 enriched, 13% were Basal-like and 
9% of them are undetermined. The prevalence of intrinsic subtypes in Chinese was 
significantly different from Caucasian (Huang et al., 2015).  
 
In Malaysia, the only study on distribution of population molecular subtype reported that 48% 
luminal A (ER+ PR+ HER2-) breast cancer, 12% Luminal B with HER2 positive 
(ER+PR+HER2+), 29% TNBC and 11% HER2 overexpressing subtypes among the 1034 
subjects (ER-PR-HER2+) (Devi et al., 2012) .  
 
2.4 Socio-Demographic Prognostic Factors of Breast Cancer 
An informative prognostic factor in should possess the following characteristic: 
• Provides significant and independent prognostic value 
• Feasible, reproducible, and widely available  
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• The conclusion is readily interpretable by the healthcare worker (Rosner an dLane, 
1991) 
2.4.1 Age 
A study in Sweden with 57,068 women included indicated that both younger or older age at 
diagnosis was associated with a poorer relative survival compared to those whose age were 
amongst the middle (Adami et al., 1986).  In a registry-based cohort of 22,017 women, patients 
age 20 to 35 years showed a worse five-year survival (74.7% compared to 83.8 – 88.3% for 
women ages 35 to 69 years) (Fredholm et al., 2009). Another research found younger age (<35) 
was an independent risk factor for disease relapse in operable breast cancer female (Han and 
Kang, 2010). Similarly, a study found young patients with breast cancer who did not receive 
adjuvant treatment were at higher risk of death from the disease (Kroman et al., 2000). The St. 
Gallen Consensus conferences back in 1998 and 2001 also indicated that age below 35 was a 
risk factor for disease relapse in women with node-negative breast cancer patients (Zujewski 
and Liu, 1998; Goldhirsch et al., 2001).  In a study of 17,575 women with stage I to III breast 
cancer, patients with ≤ 40 years of age at diagnosis showed higher breast cancer mortality as 
compared to older patients (HR: 1.4; 95%CI: 1.2,1.7) (Partridge et al., 2016). 
 
2.4.2 Ethnicity  
Surveillance, Epidemiology and End Results (SEER) study in 2013 reported that black women 
had lower rates of breast cancer screening and longer delay to the initiation of the treatment, 
thus having 12.9% poorer five-year survival compared to whites (blacks, 55.9%; whites, 
68.8%) (Silber et al., 2013). A recent review of breast cancer research in Malaysia by Yip et 
al., (2014) showed that Malays was associated with higher risk of all-cause mortality. However, 
the author also pointed out that the factors accounted for the ethnic differences were unclear. 
A study combining data from two hospitals located in Malaysia and Singapore demonstrated 
Malay ethnicity was significantly associated with larger tumour and later stage at presentation 
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compared to other races (Bhoo-Pathy et al., 2012). Ong and Yip (2000) observed the race is a 
notable predictor of recurrence-free survival but not significant forward overall survival.  
 
2.4.3 Obesity  
Protani et al. concluded in their recent systematic review and meta-analysis on some 
observational studies that obese women at the time of diagnosis had a 33% higher chance of 
disease recurrence or mortality when compared with normal-weight patient (Protani et al., 
2010). Another single centre study analysing DFS also supported the prognostic value of 
weight, where it showed among never-smoking women, those who gained between 0.5 and 
2.0 kg/m2 (relative risk: 1.35; 95% CI, 0.93 to 1.95) or more than 2.0 kg/m2 (RR: 1.64; 95% 
CI, 1.07 to 2.51) after diagnosis were at higher risk of mortality during 9 years of follow-up,  
compared with patients who had maintained their body weight  (Kroenke et al., 2005).   
 
2.4.4 Smoking 
Cigarette smoking both before and after breast cancer diagnosis had been shown to relate to 
increasing of breast cancer mortality. Patients who smoked actively during the year before the 
cancer diagnosis were at higher hazard (HR 1.25, 95% CI: 1.13, 1.37) to die compared to 
never-smokers. On top of that, women who continue smoke lifestyle after diagnosis were even 
more likely than never-smokers to die of breast cancer (HR 1.72, 95% CI 1.13, 2.60) 
(Passarelli et al., 2016). Several studies also confirm that smoker or former smoker worsens 
the prognosis after surgery among women with breast cancer (Hellmann et al., 2010; 
Braithwaite et al., 2012; Saquib et al., 2013; Sollie and Bille, 2017).  
 
2.4.5 Marital status 
A recent study indicated unmarried patients suffered a 28% higher chance of death after 




2.4.5 Parity status 
A study highlighted nulliparous status was an independent predictor of poorer breast cancer 
survival after adjusting for age (Anderson et al., 2014). However, the study also showed that 
along with no child, high parity patient (four or more children) also had significantly higher 
mortality from breast cancer when compared to women with a child (RR 1.49, 95% CI 1.20-
1.85) (Butt et al., 2009). 
 
2.4.6 Age at first childbirth and age at last childbirth 
Study showed those who had breast cancer within 5-10 years of delivery have a 62% higher 
chance to carry a poorer outcome as compared to the other (Strasser-Weippl et al., 2015). A 
study in Danish women demonstrated breast cancer patients with first childbirth between 20 
and 29 years had a significantly lower risk of death compared with women with first childbirth 
below the age of 20 years (20-24 years: RR = 0.88, 95% CI: 0.78-0.99; 25-29 years: RR = 
0.80, 95% CI : 0.70-0.91) (Kroman et al., 1998) 
 
2.5 Histopathological Prognostic Factors of Breast Cancer 
2.5.1 Multifocal or multicentric tumours 
According to a recent study, whether multifocal (i.e., invasive tumors identified within the 
same breast quadrant) or multicentric (i.e., invasive tumours identified in separate breast 
quadrants) influence prognosis was still controversial.  A study with 288 pairs of breast cancer 
female using Cox regression analysis for multivariate analyses demonstrated multifocal or 
multicentric cancer were significant predictors for  overall survival (HR = 1.57; 95% CI: NA) 
and overall-recurrence (HR = 1.74; 95% CI: NA). However, another study showed multifocal 
or multicentric breast cancer did not have predictive value on recurrence-free survival, BCSS, 




2.5.2 Tumour, Nodes, Metastasis (TNM) system 
Generally, tumour stage was a well-reported prognostic factor. The breast cancer is staged 
according to tumour size, number of lymph nodes involved, and presence of metastatic disease. 
(Tumour, Nodes, Metastasis [TNM] system). The SEER data in US revealed that five-year 
relative survival rates are 95, 85, 70, 52, 48 and 18 percent for stage I, IIA, IIB, IIIA, IIIB, and 
IV breast cancer, respectively (Newman, 2009). The data from UK (2002-2006) revealed that 
the five-year relative survival for stage I, II and III are 99%, 88% and 55% respectively 
(Cancer Research UK, 2017). 
 
2.5.3 Tumour Size 
Tumour Size (T) is defined as the greatest diameter of the primary breast tumour was an 
important prognostic factor in breast cancer (Fisher et al., 1969). The SEER database includes 
13,464 women with node-negative breast cancer. Patients with tumors <1 cm had a 5-year OS 
of close to 99% compared with 89% for tumors between 1 cm and 3 cm and 86% for tumors 
between 3 cm and 5 cm (Carter et al., 1989). This association persists with longer follow-up. 
Rosen et al. examined the relationship between tumor size and 20-year recurrence-free 
survival and found a significant association, with a 20-year recurrence-free survival of 88% 
for tumors ≤1 cm, 72% for tumors 1.1 cm to 3 cm, and 59% for tumors between 3.1 cm and 5 
cm (Rosen et al., 1993). 
 
2.5.4 Nodal Involvement 
The number of axillary nodes with metastatic tumour growth was a well-reported independent 
prognostic factor for disease recurrence or mortality. Among women without metastatic 
progression at diagnoses, the five-year survival rate for those with localized and regional 
disease was 99% and 85%, respectively (Siegel et al., 2017). Another study showed the 
survival was related to number of nodes where the five-year survival was 96, 86, and 66 % for 
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patients who were node-negative, had one to three nodes involved or had more than four nodes 
involved, respectively (Carter et al., 1989).  
 
2.5.5 Tumour morphology 
Invasive ductal carcinoma (IDC) is the most common morphology type of breast cancer which 
account for more than 70% of all breast cancer new cases, followed by invasive lobular 
carcinoma (ILC) with a frequency of about 10 % as shown in a study reviewing US SEER 
record from 1992 – 2001 (Li et al., 2005). ILC had 16% lower risk of experiencing disease 
recurrence compared to IDC during the first six years of follow-up in a study; However, ILC 
had a 54 % higher risk of disease recurrence after six years (Pestalozzi et al., 2008).  
 
2.5.6 Histologic grade 
A study with 2200 patients found a very strong correlation between long-term survival and 
Nottingham combined histologic grade (Elston and Ellis, 1991). However, The Breast Task 
Force of The American Joint Committee on Cancer had decided to remove grading from the 
current TNM staging system for breast cancer due to the grading system was limited by low 
interobserver agreement and the lack of prognostic information in grade 2 tumours (Rosner 
and Lane, 1991; Singletary et al., 2002).  
 
2.5.7 Lymphovascular Invasion  
The presence of lymphovascular invasion appeared to be a factor indicating poor disease 
prognosis. This was shown in a cohort study of 1704 patients that did not receive any systemic 
therapy, in which peritumoral lymphovascular invasion was a prognostic factor for local 
recurrence and survival (Pinder et al., 1994). In a US study comprising 166 women with 
operable invasive BC who underwent adriamycin- and taxane-based NAC between 2000 and 
2013 multivariate models adjusting for breast cancer subtype, LVI was significantly associated 
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with a decrease in progression-free survival (HR 3.76, 95 % CI 2.07-6.83, p < 0.01) and overall 
survival (HR 5.70, 95 % CI 2.08-15.64, p < 0.01) (Liu et al., 2016). 
 
2.6 Treatment-Related Prognostic Factors of Breast Cancer 
2.6.1 Adjuvant Chemotherapy 
The consideration of systemic adjuvant therapy after the surgical operation based on the 
predicted response and the possible drug adverse reaction to a treatment. The final decision on 
treatment also takes patients’ age, general health status, comorbidities and preference into 
account. Adjuvant systemic treatment started within 2 – 6 weeks after the surgery (Senkus et 
al., 2015). It was a general practice to administer systemic therapy to breast cancer patient 
with lymph node-positive breast cancer (Cianfrocca and Goldstein, 2004).  
 
Administration of anthracycline-based polychemotherapy such as FAC or FEC for about 6 
months would decrease the annual breast cancer mortality rate by 38% for women age below 
50 years and by 20%  for patients of age 50–69 years when diagnosed, regardless of the usage 
of endocrine therapy, stage, histopathological grade and ER status (EBCTCG, 2005). 
 
2.6.2 Radiotherapy 
A study reviewed 42,000 women with breast cancer in randomized treatment comparisons and 
found that those who received and completed radiotherapy treatment had much lower risk 
toward local recurrence (7% vs. 26%) and significant lower five-year overall survival (30.5% 
vs 35.9%; p=0.0002). (Clarke et al., 2005). A later meta-analysis of 10,801 operated women 
in 17 randomised trials comparing receipt of radiotherapy versus no radiotherapy confirmed 
the findings above. In this study, it showed radiotherapy reduced both 10-year risk of any local 
or distant recurrence from 35.0% to 19.3% (absolute reduction 15.7%, 95% CI 13.7–17.7, 
p<0·001) and the five-year risk of mortality from 25.2% to 21.4% (absolute reduction 3.8%, 
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95% CI: 1.6–6.0, p<0·001) (Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et 
al., 2011) 
 
2.6.3 Hormonal Therapy 
Hormone therapy or endocrine therapy played a main role in adjuvant therapy especially in 
patients with estrogen receptor positive breast cancer. American Society of Clinical Oncology 
(ASCO) suggested women with stage I to III breast cancer disease considered having 
tamoxifen for 10 years in its clinical practice guideline on adjuvant endocrine therapy for 
women with hormone receptor–positive breast cancer that published in 2014 (Burstein et al., 
2016). A study initiated by the Early Breast Cancer Trialists’ Collaborative Group noted that 
5 years administration of adjuvant tamoxifen therapy successfully reduced the risk of 
recurrence or death by a third (Davies et al., 2011). Table 2.4 summarized result from those 
studies that exploring prognostic factor of breast cancer among female patient underwent 




Table 2-4: Five-year overall survival based on whole study population and staging of cancer 
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2.7 Survival Analysis 
Survival data study the time elapsed from some particular starting point to the occurrence of 
the event. One of the distinctive characteristics of survival data compared to other types of 
analysis is the presence of censoring. In survival analysis, subjects are followed over the 
specific period until the main event of interest occurs. Only some individuals experienced the 
event in interest while the others’ are remained unknown. This phenomenon is known as 
censoring and it may occur in the following ways: 
• A subject has not yet experienced the event by the time of the closure of the study. 
• A subject is lost to follow up during the accrual period 
• A subject experienced a different event that makes further follow up impossible  
All of these situations were defined as right censoring (Bradburn et al., 2003a; Clark et al., 
2003). Most survival data include right-censored observation (Hosmer et al., 2008). Other 
types of censored data available are interval and left censored (Clark et al., 2003). 
 
The time-to-event data are generally described as survival and hazard. The survival probability 
also known as survival function of which denoted as S(t) represent the probability of an 
individual survives from the time origin toward a future time of endpoint. On the other hand, 
the hazard function of T, denoted as h(t) is the probability of an individual under observation 
has the event of interest occurred at a specific time point t in future. In sum, the survival 
indicates the cumulative not having an outcome in question, while the hazard indicates the 
chance of having an outcome in question (Clark et al., 2003).  
 
Statistical methods that are generally applied in survival analysis are Kaplan-Meier for 
univariable analysis and Cox proportional hazard model for multivariable analysis (Clark et 
al., 2003). The Kaplan-Meier survival estimator provides the probability of survive over the 
observed time frame including censored and uncensored, using the product-limit method 




Survival in two or more groups of subjects can be compared using log-rank test which is the 
most widely used method in medical research (Peto et al., 1977). The log-rank test calculates 
the number of expected events at each event time and for each group. These values are then 
summed up for all event times to obtain the total expected events in each group, denoted as Ei 
for group i, then the log-rank test compared the observed events, denoted as Oi for group I to 







The calculated value can be compared to a χ2 distribution with (g-1) degrees of freedom when 
g is the number of groups. A P-value can be calculated to determine the statistical significance 
of the differences between the survival curves (Peto et al., 1977). 
 
Length of follow-up can be determined by the median follow-up time. Patient who does not 
experience an event can be included in a survival analysis, but the completeness of follow-up 
among patients is important. Loss to follow-up may be determined by demonstrating the total 
number of subjects lost during follow-up period of the study (Clark et al., 2003).  
 
The Cox or proportional hazards model (Cox, 1972) is the most widely used multivariate 
analytical method for survival data in medical research. The survival regression model 
describes the relation between event and a number of covariates, as presented by the hazard 
function or hazards ratio. The hazard is defined as the instantaneous probability of having 
event at a given time. Clark et al. (2003) used the following formula to mathematically explains 
the Cox Model: 
ℎ(𝑡) = ℎ𝑜(𝑡)𝑥 exp(𝑏1𝑥1 + 𝑏2𝑥2 +⋯+ 𝑏𝑖𝑥𝑖) 
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where the hazard function h(t) is determined by a number of i variables, and the impact of 
variable on hazard was computed as respective coefficients (b). The ho term also known as 
baseline hazard. 
 
The objective of the study affected the choice of covariates, there are three possible scenarios 
to use a multivariable Cox model:  
1. A single variable is under investigation for its association with survival along with 
another known variable 
2. A set of variables are under investigations for their ability in predicting survival 
3. A set of variables are under investigations for their ability in predicting survival, along 
with additional known variables 
Stepwise selection is common choice for automated model building, but other approaches exist. 
Henderson and Vellemen (1981) suggested that the choices should be verified by a degree of 
munual modelling, where terms can be included or removed based on logical order rather than 
solely followed to statistical significance. Clark et al. (2003) demonstrated the rationale and 
limitation of semi-automated stepwise selection method and provided advice on hands-on 
modelling.  
 
Residuals form models are a useful method for checking the fit of a regression model. There 
are three types of residual proposed in accessing model adequacy: Martingale residual, 
deviance residual and scaled Schoenfeld residuals. In general, the residual is skewed, it needs 
to have smoothing function for easier interpretation. The scatter graph of one of the residual 
and variable or survival time shall display an evenly scattered horizontal band and no obvious 
trend shall be observed (Bradburn et al., 2003b).   
 
